^
CANCER:

Gastrointestinal Cancer

No biomarker
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive: A1 - Approval
Innovent Biologics Press Release - 5 days - (New A1)
No biomarker
HCC
durvalumab + CP-675206
Sensitive: B - Late Trials
NEJM Evidence - 2 weeks - (New B)
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
Ann Oncol - 2 weeks - (New C3)
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A1 - Approval
Ann Oncol - 2 weeks - (New C3)
NRAS mutation
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
ESMO Open - 2 weeks - (New C3)
KRAS mutation
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
ESMO Open - 2 weeks - (New C3)
LRP1B mutation + TP53 wild-type
HCC
lenvatinib
Resistant: C3 – Early Trials
Hepatol Int - 2 weeks - (New C3)
FAT1 mutation + TP53 wild-type
HCC
lenvatinib
Resistant: C3 – Early Trials
Hepatol Int - 2 weeks - (New C3)
PD-L1 expression
Gallbladder Cancer
bevacizumab
Sensitive: C4 – Case Studies
Dovepress - 2 weeks - (New C4)
RNF43 G659fs
CRC
PI3K inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
RNF43 G659fs
CRC
mTOR inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
RNF43 659
CRC
mTOR inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
RNF43 659
CRC
PI3K inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
HER-2 amplification
CRC
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
JCO Clin Cancer Inform - 3 weeks - (New C3)
BRAF V600E
CRC
bevacizumab
Sensitive: B - Late Trials
Br J Cancer - 3 weeks - (New C3)
HER-2 positive
Biliary Tract Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
FGFR4 expression
HCC
PDR001 + FGF401
Sensitive: C3 – Early Trials
J Exp Clin Cancer Res - 3 weeks - (New C3)
KLB expression
HCC
PDR001 + FGF401
Sensitive: C3 – Early Trials
J Exp Clin Cancer Res - 3 weeks - (New C3)
HER-2 G776S
CRC
afatinib
Sensitive: D – Preclinical
Sci Rep - 3 weeks - (New D)
YAP1 overexpression
HCC
sorafenib + CA3
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks - (New D)
TAFAZZIN overexpression
HCC
sorafenib + CA3
Sensitive: D – Preclinical
Cancers (Basel) - 3 weeks - (New D)
APC mutation
CRC
HMG-CoA reductase inhibitor
Sensitive: D – Preclinical
Front Oncol - 3 weeks - (New D)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive: A1 - Approval
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
CRC
bevacizumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant: A1 - Approval
No biomarker
CRC
trifluridine / tipiracil
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine / tipiracil
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
trifluridine / tipiracil
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
CRC
ziv-aflibercept IV
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
CRC
capecitabine
Sensitive: A1 - Approval
No biomarker
Pancreatic Cancer
erlotinib
Sensitive: A1 - Approval
EGFR expression
CRC
cetuximab
Sensitive: A1 - Approval
KRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
ramucirumab
Sensitive: A1 - Approval
KRAS A146
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
HCC
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
AFP elevation
HCC
ramucirumab
Sensitive: A1 - Approval
No biomarker
HCC
regorafenib
Sensitive: A1 - Approval
No biomarker
HCC
lenvatinib
Sensitive: A1 - Approval
No biomarker
HCC
sorafenib
Sensitive: A1 - Approval
KRAS G13
CRC
cetuximab
Resistant: A1 - Approval
KRAS G12
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
No biomarker
CRC
regorafenib
Sensitive: A1 - Approval
KRAS K117
CRC
cetuximab
Resistant: A1 - Approval
KRAS A59
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
HCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
KRAS G12S
CRC
panitumumab
Resistant: A1 - Approval
NRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
NRAS Q61
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
panitumumab
Resistant: A1 - Approval